Neurocrine Biosciences
NBIX
#1469
Rank
NZ$25.10 B
Marketcap
NZ$251.82
Share price
2.23%
Change (1 day)
5.00%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2025 (TTM): NZ$7.40

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is NZ$7.49. In 2024 the company made an earnings per share (EPS) of NZ$5.87 an increase over its 2023 EPS that were of NZ$4.41.

EPS history for Neurocrine Biosciences from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)NZ$7.4026.01%
2024NZ$5.8733.07%
2023NZ$4.4157.76%
2022NZ$2.8069.47%
2021NZ$1.65-78.21%
2020NZ$7.57990%
2019NZ$0.6981.82%
2018NZ$0.38-113.5%
2017NZ-$2.830.62%
2016NZ-$2.8157.28%
2015NZ-$1.7925.61%
2014NZ-$1.4218.84%
2013NZ-$1.20-1085.71%
2012NZ$0.12

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Repligen
RGEN
NZ$0.05210-99.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
NZ$3.07-59.02%๐Ÿ‡ฌ๐Ÿ‡ง UK
Palatin Technologies
PTN
NZ-$51.93-793.74%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$35.63 376.06%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
NZ$2.35-68.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
NZ$2.99-60.09%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
NZ$2.97-60.32%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
NZ-$3.53-147.10%๐Ÿ‡บ๐Ÿ‡ธ USA